UK markets closed

Kobayashi Pharmaceutical Co., Ltd. (KOY.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
32.00+0.60 (+1.91%)
At close: 08:05AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 2.44B
Enterprise value 1.96B
Trailing P/E 19.55
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.29
Price/book (mrq)1.90
Enterprise value/revenue 0.01
Enterprise value/EBITDA 0.06

Trading information

Stock price history

Beta (5Y monthly) 0.26
52-week change 3-41.82%
S&P500 52-week change 322.38%
52-week high 355.50
52-week low 328.00
50-day moving average 333.76
200-day moving average 339.72

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 574.34M
Implied shares outstanding 676.1M
Float 843.41M
% held by insiders 135.40%
% held by institutions 113.79%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.74
Forward annual dividend yield 42.36%
Trailing annual dividend rate 3101.00
Trailing annual dividend yield 3321.66%
5-year average dividend yield 41.03
Payout ratio 437.66%
Dividend date 3N/A
Ex-dividend date 427 Jun 2024
Last split factor 22:1
Last split date 328 Jun 2016

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 11.73%
Operating margin (ttm)11.72%

Management effectiveness

Return on assets (ttm)6.12%
Return on equity (ttm)10.10%

Income statement

Revenue (ttm)173.45B
Revenue per share (ttm)2,287.06
Quarterly revenue growth (yoy)4.50%
Gross profit (ttm)N/A
EBITDA 31.68B
Net income avi to common (ttm)20.34B
Diluted EPS (ttm)1.64
Quarterly earnings growth (yoy)-12.40%

Balance sheet

Total cash (mrq)79.84B
Total cash per share (mrq)1,073.95
Total debt (mrq)987M
Total debt/equity (mrq)0.48%
Current ratio (mrq)2.82
Book value per share (mrq)2,755.17

Cash flow statement

Operating cash flow (ttm)18.36B
Levered free cash flow (ttm)2.53B